Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
Joseph M. Rocco, Lindsey B. Rosen, Gloria Hong, Jennifer Treat, Samantha Kreuzburg, Steven M. Holland, Christa S. Zerbe
Journal of Translational Autoimmunity · 2021-01
Abstract
Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to reduce autoantibodies leading to clinical and radiographic improvement in infection.
MeSH terms
- Medicine
- Rituximab
- Autoantibody
- Refractory (planetary science)
- Bortezomib
- Nontuberculous mycobacteria
- Immunology
- Internal medicine